We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against the ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during trading on Friday after HC Wainwright raised their price target on the stock from $190.00 to $200.00. HC ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company ...

Axsome Therapeutics' stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth, but I maintain a "sell" rating. Despite Auvelity's revenue growth, significant ...

Significant R&D investment of $55 million highlights a focus on pipeline development. Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than ...

Axsome Therapeutics, a biopharmaceutical company targeting central nervous system (CNS) disorders, develops novel therapies for depression, narcolepsy, and other CNS conditions. Its current ...